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Abstract
Background:  Due to its strong intra- and inter-individual variability, predicting the ideal
erythropoietin dose is a difficult task. The aim of this study was to re-evaluate the impact of the
main parameters known to influence the responsiveness to epoetin beta and to test the
performance of artificial neural networks (ANNs) in predicting the dose required to reach the
haemoglobin target and the monthly dose adjustments.
Methods: We did a secondary analysis of the survey on Anaemia Management in dialysis patients
in Switzerland; a prospective, non-randomized observational study, enrolling 340 patients of 26
centres and in order to have additional information about erythropoietin responsiveness, we
included a further 92 patients from the Renal Services of the Ente Ospedaliero Cantonale,
Bellinzona, Switzerland. The performance of ANNs in predicting the epoetin dose was compared
with that of linear regressions and of nephrologists in charge of the patients.
Results: For a specificity of 50%, the sensitivity of ANNs compared with linear regressions in
predicting the erythropoietin dose to reach the haemoglobin target was 78 vs. 44% (P < 0.001).
The ANN built to predict the monthly adaptations in erythropoietin dose, compared with the
nephrologists' opinion, allowed to detect 48 vs. 25% (P < 0.05) of the patients treated with an
insufficient dose with a specificity of 92 vs. 83% (P < 0.05).
Conclusion: In predicting the erythropoietin dose required for an individual patient and the
monthly dose adjustments ANNs are superior to nephrologists' opinion. Thus, ANN may be a
useful and promising tool that could be implemented in clinical wards to help nephrologists in
prescribing erythropoietin.
Background
Stable haemoglobin levels maintained in the target range
of 11 to 12 g/dL as recommended by the Kidney Disease
Outcomes Quality Initiative, are associated with both
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clinical and quality of life benefits as well as a reduction
in hospitalisation and mortality [1-4]. Whether, in tar-
geted subgroups, the haemoglobin concentration should
be set above 12 g/dL has not been definitively demon-
strated [5]; however, considering the likelihood of
increasing thrombotic events [6,7], its value should not
exceed 14 g/dL [5].
The response to erythropoietin is known to have a large
inter- and intra-individual variability explained by blood
losses, co-morbidities [8], dialysis efficiency [9,10], iron
status [5,11], folic acid and vitamin B12 deficiency [12],
hyper- and hypo-parathyroidism [13,14], pro-inflamma-
tory cytokine activities [15], aluminium toxicity [14],
treatment with angiotensin converting enzyme inhibitors
(ACE-I) [16] and probably angiotensin II receptor block-
ers (ARB) [17]. Thus, maintaining the haemoglobin level
in the target range is sometimes a difficult task which
necessitates regular doses adjustments.
To optimize anaemia management several protocols,
based on physician or nurse-driven algorithm as well as
computer assisted prescription tools, some of them
involving the use of Artificial Neural Networks (ANNs),
have been described [18-26].
A large amount of clinical and biochemical data that
could be useful in making crucial follow-up decisions are
actually collected during dialysis sessions [27-29]. Unfor-
tunately the multidimensionality and at least partial non-
linearity of the data, (i) limits the value of both intuition/
experience of the nephrologists and standard statistical
procedures and (ii) makes their interpretation and practi-
cal use in clinical wards difficult [27]. The importance of
individualizing drug dosage regimens by adding patient-
specific post-administration data about serum levels or
responsiveness to population pharmacokinetic and
dynamic models, has been thoroughly demonstrated
[30]. Compared to other non linear mathematical and sta-
tistical tools based for instance on Bayesian fitting and
adaptive control, ANNs have the advantage of being user
friendly, tolerating missing data and errors in individual
variables well and also of being applicable to translate
multivariate non-linear relationships into continuous
functions without the need of understanding precisely the
underlying relationships between variables [31-36].
ANNs have been widely used in clinical medicine and
have already assisted nephrologists in solving various
complex clinical problems [27-33,37,38].
The purposes of the present study were (i) to characterize
the linear or non-linear relationships between several
clinical and biological variables and the response to epo-
etin beta and (ii) to build a computer assisted mathemat-
ical tool able to predict the epoetin requirement in an
individual patient and the monthly adjustments in the
epoetin dose.
Methods
Patient characteristics
We did a secondary analysis of the survey on Anaemia
Management in dialysis patients in Switzerland (AIMS); a
prospective, open label, non-randomized observational
study designed to assess anaemia management in the dial-
ysis centres in Switzerland [Lötscher N, et al. Swiss Med
Forum 2004; 4: S7; Abstract]. In this study (inclusion and
exclusion criteria were: current dialysis treatment, age > 18
y, renal anaemia requiring epoetin therapy, ferritin > 200
μg/L and respectively absence of vitamin B12 or folic acid
deficiency, unstable angina pectoris, untreated hyperten-
sion, haemoglobinopathy, haemolysis, epilepsy), data
about sex, weight, age, presence or absence of a diabetes
mellitus and/or a cardiomyopathy, haemoglobin, epoetin
beta dose and its administration route (subcutaneous vs.
intravenous), ferritin and creatinine were collected in 340
hemodialysis patients. In order to increase the statistical
power of the study and to gain more information about
factors influencing erythropoietin responsiveness, a fur-
ther 92 haemodialysis patients (with complete historical
data and selected with the same criteria applied for the
AIMS survey) were included in the analysis. These addi-
tional patients were selected based on the same inclusion
criteria from the Renal Services of the Ente Ospedaliero
Cantonale (EOC), Bellinzona, Switzerland after having
been followed for at least 12 months (the 2 databases
pooled together being called AIMSEOC data). For each
patient the sex, weight and age, the haemoglobin, epoetin
beta dose and its administration route (subcutaneous vs.
intravenous), ferritin, creatinine, urea, Kt/V, pH, phos-
phate, ionized calcium, albumin, parathyroid hormone
(PTH), C reactive protein (CRP) and intravenous iron
dose over the 12 treatment months were collected.
Comorbidity information about the concomitance of dia-
betes mellitus, cardiomyopathy with impaired left ven-
tricular ejection fraction (<50%) and ACE-I or ARB
medication were also registered.
Kt/V calculation
The Kt/V, a parameter of dialysis adequacy defined as the
dialyzer clearance of urea multiplied by the duration of
the dialysis treatment and divided by the volume of distri-
bution of urea in the body, was estimated with a second
generation single-pool Daugirdas formula [39]: Kt/V = -ln
(R -0.03) + [(4-3.5 × R) × (UF/W)] where: R = post-dialysis
urea/pre-dialysis urea, UF = net ultrafiltration and W =
weight.BMC Nephrology 2006, 7:13 http://www.biomedcentral.com/1471-2369/7/13
Page 3 of 11
(page number not for citation purposes)
Estimation of the erythropoietin dose required to obtain a 
haemoglobin of 11.5 g/dL
To calculate the epoetin dose that should have been pre-
scribed in order to obtain a haemoglobin of 11.5 g/dL a
linear regression plotting epoetin dose against haemo-
globin was built for each patient. The choice of using sub-
optimal tools like linear regressions to estimate the ideal
epoetin dose was made considering that (i) the small
number of observations reduced the statistical options at
our disposal and (ii) an epoetin dose approximating the
ideal one was necessary to build the models.
Artificial Neural Networks
In order to build the non-linear continuous functions
expressing the interdependency between the collected
data and the epoetin dose a series of artificial neural net-
works (ANNs) were built, trained, cross-validated and
tested using the NeuroSolution for Excel 4.32 software,
NeuroDimension Inc.
ANNs are composed of one input layer (collecting input
variables expected to be predictive), one output layer (col-
lecting the predictions, known in training and unknown
in testing and validation cases) and one or more hidden
layers (performing a weighted sum of the inputs and pass-
ing the resulting value through a non-linear function to
the output layer). Individual weights are progressively
adapted, using for instance a back-propagation algorithm,
to minimize the difference between calculated and
expected outputs; the weights assuring the best results
then being used to test and compare the performance of
the ANNs (see Figure 1 for a schematic representation).
The databases selected to be analyzed were randomized
using the same software package. After selecting 25% of
the data for the validation phase, the remaining pool was
divided into the training, cross validation and testing sub-
groups assigning respectively to each one 50, 10 and 40%
of the data. As a network structure only Multilayer Percep-
trons (MLP) (layered feed-forward networks trained with
static backpropagation) and Generalized Feedforward
Networks (GFN) (generalization of the MLP with connec-
tions jumping over hidden layers) were used (see Figure
1). Seeing that the critical difference between the two net-
work structures is the amount of training data requested
to optimize the performance (higher in the MLP and
lower in the GFN) and because of the database with a lim-
ited extension used, each set of variables was used to train
both models. A hyperbolic tangent transfer function
(maximum and minimum output 1 and -1 respectively),
as recommended by the producer (default setting), was
chosen for each neuron. All initial connection weights
were randomized before beginning a training phase. As a
learning rule a gradient and weight change one (momen-
tum) was chosen. To avoid overtraining, the training
phase was stopped when the minimum squared error
(MSE), displayed as a function of the training epochs,
between the predictions and the desired output in the
cross validation subgroup (indirect indicator of the level
of generalisation) began to increase. All the networks were
built using only one hidden layer while the ideal number
of hidden neurons was determined by training, cross val-
idating and testing a MLP, increasing unitarily the number
of neurons beginning with 4 and stopping when the MSE
between the predictions and the desired output in the test-
ing subgroup began to increase. Once a definitive MLP
was obtained, its performance was compared with a GFN
with an identical number of processing elements (being
both trained, cross validated and tested 5 times) and the
best performing model (best compromise in the testing
subgroup between linear correlation and normalized
mean squared error r/NMSE) (see "Statistical and data
analysis" paragraph for details) was selected to be tested
in the validation subgroup. All studied variables were first
analyzed separately and then combined in order to
achieve the best prediction performance. The study was
designed according to the prescriptions of Cross et al.
[33].
Prediction by the nephrologists in charge of the patients of 
a follow-up haemoglobin level below the target of 11.0 g/
dL
The sensitivity, specificity and the positive and negative
predictive values in detecting a follow-up haemoglobin <
11.0 g/dL were calculated by interpreting the decision of
the nephrologists to increase the epoetin dose as if it had
Schematic representation of an artificial neural network Figure 1
Schematic representation of an artificial neural net-
work. A typical ANN consisting of one input layer, two hid-
den layers and one output layer is represented. The basic 
structure, fed forwards and trained by back-propagation is 
called Multilayer Perceptron (MLP) while models designed 
with connections jumping over hidden layers (---) are called 
Generalized Feedforward Networks (GFN).BMC Nephrology 2006, 7:13 http://www.biomedcentral.com/1471-2369/7/13
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been a prediction of a follow-up haemoglobin below the
target level. Respecting statistical and modeling exigencies
the haemoglobin measured one month after the adapta-
tion in the dose has been considered as the follow-up hae-
moglobin.
Selection of the data for the prediction of the monthly 
epoetin dose adjustments
The data necessary to build and test the ANN predicting
the monthly epoetin dose adjustments were selected from
the AIMSEOC  pool. Complete data of 4 consecutive
months from months 3 to 6 and/or 7 to 10 were
requested. The data of the months 3–5 and 7–9 were used
as input while the data of months 6 and 10 were used as
desired output.
Statistical and data analysis
Statistical and data analysis was performed using a statis-
tical software package (SPSS 12.0; SPSS Inc.). SPSS was
also used to build linear regressions (forward stepwise
method based on the F probability including collinearity
diagnostics) and to infer receiver-operating-characteristic
curves (ROC) plotting the sensitivity against 1 minus the
specificity for each prediction from the ANN, the linear
regressions or the nephrologists (the areas under the
curves were calculated by the trapezoidal nonparametric
method and are expressed with the 95% confidence inter-
val). Accuracy was expressed by the Combined Root Mean
Square Error (CRMSE) calculated as the square root of
[(mean difference in estimate-observed)2  + (standard
deviation of the difference)2]. Agreement between the pre-
dictions and the basis data was expressed by "limits of
agreement", "95% confidence interval for the bias" and
"95% confidence interval for the lower and upper limits
of agreement" according to Bland and Altman [40]. The
mean difference in estimate – observed, also called "bias",
and the standard deviation of the difference of the same
subtraction, also called "precision" are included concepts
in both CRMSE and "limits of agreement". Histograms
comparing the performance of the ANNs and the best per-
forming linear regression were built using Excel SP3,
Microsoft Inc. With the intention of facilitating the graph-
ical representation of the differences in the predictive per-
formances the ratio r/NMSE was calculated dividing the
Pearson linear correlation coefficient r by the normalized
mean squared error (obtained dividing the mean squared
error by the variance of the reference population); the
higher the value the better the performance. Percentages
were compared using a Fisher exact test. The values are in
mean ± standard deviation (SD). A P-value < 0.05 was
considered statistically significant.
Results
Population characteristics
The 12-month follow-up of the AIMS survey was initiated
in June 2002. 340 patients from 26 centres were included
in the final analysis. The mean age of the participating
patients was 63 ± 15 y. The most common causes of end-
stage renal disease were glomerulonephritis (23%), dia-
betic nephropathy (21%) and hypertension (21%). The
most prevalent baseline co-morbidities were cardiac-
related. Hypertension occurred in 61% of the patients and
diabetes was reported in 27%. The mean haemoglobin
concentration was 11.8 ± 1.4 g/dl with approximately
80% of the included patients achieving the target haemo-
globin of at least 11 g/dL. The mean epoetin beta dose was
149 ± 104 IU/kg/week.
Ninety-two patients (1104 monthly clinical and biochem-
ical data) of the 3 dialysis units of the renal services of the
Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzer-
land, all meeting the requisite criteria, were also included
in the analysis.
The basic information including comorbidity incidence,
ACE-I or ARB treatment and mean results of the monthly
biochemical parameters of the AIMS and EOC data pools
are listed in Table 1 (recurrent abbreviations in the tables
and figures are summarized in Table 2).
Intra- and inter-individual variability of the epoetin dose
In the 2 databases pooled together (AIMSEOC data) the
intra- and inter-individual variability in the epoetin dose
prescribed, expressed by the mean absolute deviation
from the mean, were 24.7 ± 27.1 and 49.8 ± 48.0 U/Kg/
week (P < 0.001) respectively.
Linear correlations between variables and epoetin dose
In the same data pool the variables correlating signifi-
cantly in a multiple linear regression with the epoetin
dose (after intra- or extrapolation for a haemoglobin of
11.5 g/dL) were weight (standardized coefficient beta (β):
-1.673; p < 0.001), ferritin (β: 0.079; P < 0.001), age (β: -
0.800; P < 0.05), epoetin administration route (subcuta-
neous vs. intravenous) (β: -22.730; P < 0.05) and presence
or absence of a cardiomyopathy (β: 33.050; P < 0.01). The
obtained linear model with a constant of 301.686 (P <
0.001) explained 40.3 % of the variability in the epoetin
dose (1.6 % imputable to the epoetin administration
route; the intravenous one being associated with an epoe-
tin dose 22.73 U/Kg/week higher). Taking the hemo-
globin (before the intra- or extrapolation process) as a
dependent variable, the epoetin dose (β: -0.003) and the
epoetin administration route (subcutaneous vs. intrave-
nous) (β:-0.528) were the only two significant variables (P
< 0.001 in both cases) in building a linear model (con-
stant: 12.980, R: 0.405). The epoetin administration routeBMC Nephrology 2006, 7:13 http://www.biomedcentral.com/1471-2369/7/13
Page 5 of 11
(page number not for citation purposes)
explained 10.2% of the haemoglobin variability in the
model; the intravenous one being associated with a lower
haemoglobin by 0.528 g/dL.
Non-linear correlations between variables and epoetin 
dose
The results of the data analysis, performed with both the
AIMSEOC and the EOC data to evaluate the non-linear
impact of individual variables in the prediction of the
mean epoetin dose required for an individual patient to
reach the haemoglobin target of 11.5 g/dL are depicted
graphically in Figure 2 (Panels A and B). In both Panels
the prediction power of individual and grouped variables
is compared in a performance gradient using the ratio
between the correlation r  and the normalized mean
square error (the higher the value the better the perform-
ance). In Panel A the prediction power of the variables of
the AIMSEOC data pool is compared with the result of the
best performing linear regression (based on weight and
serum ferritin). In Panel B the prediction power of the var-
iables of the EOC data pool is shown. The final network
structure (either Multilayer Perceptrons (MLP) or Gener-
alized Feedforward Networks (GFN) and number of
processing elements in the hidden layer) is specified, in
both figures, in the label of the ANN used for the predic-
tion.
Prediction of the epoetin requirement in an individual 
patient
The linear regressions, performed for each individual
patient, plotting epoetin dose against haemoglobin with
the aim of estimating the epoetin dose that should have
been prescribed in order to obtain a haemoglobin of 11.5
g/dL, allowed, with a r value of 0.247 ± 0.237, to obtain
an intrapolated value in 91% of the patients and an
extrapolated one in 9%.
The prediction ability of the best performing linear regres-
sion (using as input variables weight and ferritin; β:-1.865
and 0.113 respectively; P < 0.001 for both; R:0.431; con-
stant: 235.141) and ANN (using as input variables weight,
age, presence or absence of an impaired left ventricular
ejection fraction, serum creatinine and ferritin) is further
compared using ROC curves in Figure 3 (epoetin dose cut-
off 100 IU/Kg/week).
Prediction of the monthly epoetin dose adjustments
For the prediction of the monthly epoetin dose adjust-
ments required to maintain the haemoglobin in the target
range the training, cross-validation, testing and validation
data pool consisted respectively of 200, 40, 140 and 110
monthly clinical and biochemical data taken from the
AIMSEOC pool, including for each individual the haemo-
Table 1: Characteristics of the studied populations
AIMS data (± SD) EOC data (± SD)
N 340 92
Sex (% of males) 58.2 45.6
Age (y) 63.5 ± 14.6 69.7 ± 12.1
Weight (kg) 69.5 ± 15.3 69.9 ± 15.4
Diabetes mellitus (%) 27.4 34.7
Cardiomyopathy (%) 16.5 13.0a
ACE-I or ARB treatment (%) No data 89.1
Haemoglobin g/dLb 11.8 ± 1.4 11.6 ± 0.7
Creatinine μmol/Lb 580 ± 156 552 ± 145
BUN mmol/Lb No data 24.6 ± 6.0
Kt/V No data 1.33 ± 0.26
pHb No data 7.36 ± 0.04
Phosphate mmol/Lb No data 2.00 ± 1.38
Ionized calcium mmol/Lb No data 1.20 ± 0.07
Albumin g/Lb No data 37.9 ± 2.9
Ferritin mg/mL 411 ± 297 482 ± 255
PTH pmol/L No data 25.8 ± 21.9
CRP mg/Lb No data 15.7 ± 15.8
Iron intravenously mg/month No data 134 ± 50
Epoetin beta dose IU/Kg/week to reach a haemoglobin of 11.5 g/dL 149 ± 104 107 ± 63
Epoetin administration route % of subcutaneous 71 0
a only patients with a left ventricular ejection fraction <50%; b pre-dialysis values
Anthropometric data, comorbidity incidence, ACE-I or ARB treatment and mean results of the monthly biochemical parameters of the AIMS and 
EOC data pools.BMC Nephrology 2006, 7:13 http://www.biomedcentral.com/1471-2369/7/13
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globin and epoetin dose of the two previous months and
the haemoglobin of the following one. The mean haemo-
globin from the current observation (Hb), the 2 previous
(Hb-1 and Hb-2) and the following (Hb+1) month and
the mean epoetin dose from the current observation
(EPO) and the 2 previous (EPO-1 and EPO-2) months
were as follows: Hb: 11.51 ± 1.14, Hb-1: 11.55 ± 1.14, Hb-
2: 11.54 ± 1.13, Hb+1: 11.52 ± 1.04, EPO: 83.97 ± 60.67,
EPO-1: 87.05 ± 60.15, EPO-2: 85.34 ± 58.00. The remain-
ing variables did not give a significant contribution in
building an efficient non linear model and were excluded
from the final algorithm.
The accuracy, the agreement and the r/NMSE ratio in pre-
dicting the haemoglobin of one month later (follow-up
haemoglobin) by the nephrologists in charge of the
patients and the best performing ANN (using as input var-
iables the haemoglobin and epoetin dose from the current
and the 2 previous months and being structured as a Gen-
eralized Feedforward Network with 6 hidden neurons) is
depicted in Table 3. The prediction ability of both the
nephrologists and the ANN is demonstrated using ROC
curves in Figure 4 (haemoglobin cut-off 11.0 g/dL).
The sensitivity, the specificity, the positive and negative
predictive value in predicting a follow-up haemoglobin <
11.0 g/dL of the best performing ANN compared with the
nephrologists were 0.48 (27/56) versus 0.25 (14/56) P <
0.05, 0.92 (132/143) versus 0.83 (119/143) P < 0.05, 0.71
(27/38) vs. 0.39 (14/36) P < 0.01 and 0.82 (132/161) vs.
0.73 (119/162) n.s. respectively.
Discussion
This study was performed in order to characterize once
more the linear and non-linear relationship between sev-
eral clinical and biological variables and the response to
epoetin beta and to test the performance of non-linear
mathematical models, based on artificial neural networks,
in the prediction of the erythropoietin dose required for
an individual patient. Our results show that ANNs which
could be implemented in wards are clearly superior to lin-
ear regressions or the nephrologist's opinion in predicting
the erythropoietin dose for an individual patient.
The first observation of this study is that linear regressions
are less performant than ANNs as predictive tools. Indeed,
as illustrated in Figure 3, in contrary to non-linear mathe-
matical models based on ANNs, the best performing lin-
ear regression did not demonstrate any significant ability
to predict erythropoietin responsiveness. This perform-
ance gap confirms a non-linear relationship between fac-
tors influencing both erythropoietin responsiveness and
Table 2: Abbreviations
Anaemia Management in dialysis patients in Switzerland AIMS
Renal units of the Ente Ospedaliero Cantonale, Bellinzona, Switzerland EOC
AIMS and EOC data pooled AIMSEOC
Artificial neural network ANN
Linear regression LIN REG
Nephrologist NEPH
Sex SEX
Age AGE
Weight W
Diabetes mellitus DM
Cardiomyopathy CARDIO
Angiotensin converting enzyme inhibitor or angiotensin receptor blocker treatment ACE/ARB
Haemoglobin HB
Creatinine a CREA
Blood urea nitrogen a BUN
Kt/V KTV
pH a PH
Phosphate a PO4
Ionized calcium a CA
Albumin a ALB
Ferritin FERR
Parathyroid hormone PTH
C reactive protein CRP
Iron intravenously IRON
Epoetin administration route subcutaneous vs. intravenous SC/IV
normalized mean squared error divided by the Pearson correlation coefficient NMSE/r
a pre-dialysis values
Summary of the abbreviations recurrent in the tables and figuresBMC Nephrology 2006, 7:13 http://www.biomedcentral.com/1471-2369/7/13
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Performance ability of individual and combined variables in predicting the epoetin dose Figure 2
Performance ability of individual and combined variables in predicting the epoetin dose. Performance ability of 
individual and combined variables in predicting the mean epoetin beta dose required for an individual patient to reach the hae-
moglobin target of 11.5 g/dL using ANNs and linear regressions. The performance ability is expressed by the r/NMSE (the 
higher the value the better the performance). The network structure (either Multilayer Perceptron (MLP) or Generalized 
Feedforward Network (GFN) and number of processing elements in the hidden layer) is specified in the label of the ANN used 
for the prediction. Panel A: data from the AIMSEOC (training, cross-validation, testing and validation data pool: 170, 30, 122 and 
110 patients respectively); the column of the linear regression is in black; individual variables are highlighted in grey. Panel B: 
data from the EOC alone (training, testing and validation data pool: 60, 10 and 22 patients respectively).BMC Nephrology 2006, 7:13 http://www.biomedcentral.com/1471-2369/7/13
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need in individual patients. As highlighted in previous
studies [41,42], on the basis of the results of the linear
regressions, the administration route of erythropoietin
significantly influenced the erythropoietin dose: patients
treated with intravenous erythropoietin required a higher
erythropoietin dose (16.0% more) and had lower haemo-
globin (0.53 g/dL less).
Analysing the AIMSEOC  data pool, the main variables
influencing the mean erythropoietin dose needed to
obtain a haemoglobin of 11.5 g/dL were weight, drug
administration route (subcutaneous vs. intravenous), age
and ferritin (see Figure 2 Panel A). Among these variables
the relevance of the correlation with the weight has to be
considered cautiously since the epoetin dose in the AIM-
SEOC database was indexed to body weight and in a pre-
vious study the absence of justification for body weight
adjusted dosage was demonstrated [43]. Confirming pre-
vious epidemiological and experimental data, the analysis
of the EOC subgroup allowed the identification of further
variables showing a relevant non linear relationship: par-
ticular attention should be given to pH, Kt/V, PTH and
CRP (see Figure 2 Panel B) [9,10,13-15].
The good performance of the ANN built using as input
variables weight, epoetin administration route, age, pres-
ence or absence of cardiomyopathy and creatinine is
shown in Figure 3 (ROC curves). For a specificity of 50%,
the sensitivity of ANNs compared with linear regressions
in predicting the erythropoietin dose to reach the haemo-
globin target was 78 vs. 44% (P < 0.001). Considering that
the cited variables are included in the blood tests usually
performed before starting an epoetin substitution, addi-
tional information about erythropoietin responsiveness
could be easy obtained without supplementary costs.
Curiously enough not one of the cited variables contrib-
uted significantly in the building of the model structured
to predict the monthly adaptations in epoetin dose in
individual patients. This means that, as suggested by phar-
macodynamic models for other drugs [44] and as con-
firmed by the results of previous studies [24,26], the
monthly fluctuations in haemoglobin as a function of the
erythropoietin dose over a 3-month period are indirectly
expressing all the other tested parameters related, in an
analogous non linear mathematical model, to erythropoi-
etin responsiveness. Of note, a large intra- and inter-indi-
vidual variability in the requirements of erythropoietin
Table 3: Prediction ability of the nephrologists compared to 
ANNs
Nephrologists ANN
Mean absolute error 0.24 -0.02
SD 0.8972 0.8184
CRMSE 0.9279 0.8186
LA -1.5577 -1.6519
2.0311 1.6218
95%CI bias 0.1310 -0.1115
0.3424 0.0814
95% CI lower -1.7408 -1.8189
-1.3746 -1.4849
95% CI upper 1.8480 1.4548
2.2142 1.7889
NMSE 0.8020 0.6239
r Pearson 0.5337 0.6135
r/NMSE 0.6654 0.9831
Accuracy expressed by the Combined Root Mean Square Error 
(CRMSE) and agreement expressed by the "limits of agreement" (LA), 
the "95% confidence interval for the bias" (95% CI bias), the "95% 
confidence interval for the lower (95% CI lower) and upper (95% CI 
upper) limits of agreement", the Normalized Mean Squared Error 
(NMSE), the Pearson linear correlation r and the r/NMSE ratio in the 
prediction of the haemoglobin one month later.
Prediction of the epoetin dose required to reach the haemo- globin target Figure 3
Prediction of the epoetin dose required to reach the 
haemoglobin target. ROC curves plotting sensitivity 
against 1 minus specificity for a epoetin dose cut-off of 100 
IU/Kg/week in the prediction of the dose required for an 
individual patient to reach the haemoglobin target of 11.5 g/
dL obtained from the best performing linear regression (dotted 
line; using as input variables weight and ferritin) and the best 
performing ANN (continuous line; using as input variables 
weight, age, presence or absence of an impaired left ventricu-
lar ejection fraction, serum creatinine and ferritin). The areas 
under the curves, the 95% confidence intervals and the signif-
icance P for the linear regression and the ANN were respec-
tively: 0.491 (0.416–0.565), P:n.s. and 0.728 (0.663–0.794), P 
< 0.001 (P < 0.001 for the difference between the two 
curves).BMC Nephrology 2006, 7:13 http://www.biomedcentral.com/1471-2369/7/13
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(17.5 ± 19.2 and 35.3 ± 34.0 % respectively), to be
referred at least in part to the inclusion in the study even
of patients with intercurrent illnesses susceptible to influ-
ence the haemoglobin value, making the prediction of the
ideal dose particularly difficult, was found in our data-
base.
Compared with the nephrologists in charge of the
patients, following the European best practice guidelines,
the best performing ANN built to predict the monthly
adaptations in epoetin dose on the basis of the haemo-
globin and of the epoetin prescribed in the previous two
months would allow the detection of 48 vs. 25% of the
patients treated with an insufficient dose with a specificity
of 92 vs. 83% (positive and negative predictive values 71
vs. 39 and 82 vs. 73% respectively). Only in 2 cases (0.8%
of the tested group) the follow-up haemoglobin of the
patients selected to be treated with a higher epoetin dose
would have been > 12.0 g/dL (12.1 and 12.8 g/dL respec-
tively) without adaptation in the dose. This finding, com-
pared with the performance of the nephrologists in the
same group (the epoetin dose would have been increased
in 4 patients with a follow-up haemoglobin > 12.0 g/dL
without adaptation in the dose), offers sufficient guaran-
tees for the application of the selected ANNs in the clinical
setting. Furthermore, compared with previous studies
(Table 4), the present one was conducted on a larger mul-
ticentric group of patients (432 from 29 dialysis units)
with a strong inter-individual variability. This fact should
guarantee the applicability of the models beyond the
studied population. However, considering that increasing
the prediction power of the nephrologists is not the only
condition needed to promote efficiency in erythropoietin
prescription, the real impact of our computer assisted tool
has to be evaluated in a prospective randomized trial.
Coming back to the choice of using ANNs as a non linear
adaptive learning machine for individualizing epoetin
dosage regimens, their usefulness by clinical ward ori-
ented nephrologists has been demonstrated once again.
However even if compared to other computer assisted
mathematical models for non linear adaptive modeling
ANNs are easy to use and to access and tolerate both miss-
ing data and errors in individual variables well, their user
friendliness contrasts with the still persisting difficulties in
correctly evaluating the reliability of the obtained func-
tions [34-36].
The next step will be to include in the electronic docu-
mentation of the dialysis patients in use in our centres
individualized models automatically warning the neph-
rologists about the need and modality of adaptations in
the epoetin dose.
Conclusion
Compared with linear models, computer assisted tools
based on artificial neural networks predict the mean
erythropoietin dose required for an individual patient sig-
nificantly better. Surprisingly using non linear correla-
tions the most important variable influencing the epoetin
requirement expressed in units/kg/week is the weight.
Even if a particular attention should be reserved to both
the pre-dialysis pH and the epoetin administration route,
a prediction tool built with other variables known to
influence the epoetin responsiveness will not increase in a
quantitatively significant way the prediction power of the
model.
As expected the model built to predict the dose adjust-
ments is mainly influenced by the historical haemoglobin
levels and even using only the data of the previous 2
months would allow compared with nephrologists, with
a specificity of 92%, to detect a further 23% of the patients
treated with an insufficient dose of erythropoietin.
Prediction of the follow-up haemoglobin Figure 4
Prediction of the follow-up haemoglobin. ROC curves 
plotting sensitivity against 1 minus specificity for a cut-off of 
11.0 g/dL in the prediction of the haemoglobin one month 
later obtained from the nephrologists (dotted line) and from 
the best performing ANN (continuous line) (using as input vari-
ables the haemoglobin and epoetin dose from the currently 
and the 2 previous months). The areas under the curves, the 
95% confidence intervals and the significance P for the Neph-
rologists and the ANN were respectively: 0.772 (0.702–
0.881), P < 0.001 and 0.822 (0.758–0.887), P < 0.001(the dif-
ference between the two curves was not significant).BMC Nephrology 2006, 7:13 http://www.biomedcentral.com/1471-2369/7/13
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Thus, implementing computer assisted tools that help
predict the ideal erythropoietin dose, allowing timely and
appropriate prescription adjustments, is an important
challenge that will have relevant consequences on the
patients' quality of life and should be further encouraged.
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